Investors increasingly view AI as a defining theme in biotechnology, yet the ways to gain exposure vary widely. RXRX, or Recursion Pharmaceuticals, uses AI and automation to discover drug candidates internally and through partnerships. TWST, or Twist Bioscience, supplies the synthetic DNA and tools that power drug discovery and next-generation sequencing. This stock comparison is relevant to growth-oriented traders and investors weighing two AI-adjacent names with sharply contrasting market positioning, financial profiles, and recent price behavior. Understanding their relative performance and momentum can help clarify which business is better positioned in the current market environment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recursion Pharmaceuticals is a clinical-stage biotechnology company that applies AI, machine learning, and automated lab systems to industrialize drug discovery. Because it has no approved products, its revenue comes primarily from collaboration and grant agreements with partners such as Sanofi, Roche/Genentech, Bayer, and Merck KGaA.
In recent weeks, RXRX has shown modest positive moves on catalyst-driven news. The company reached alignment with the U.S. Food and Drug Administration (FDA) on the Phase 3 trial design for REC-4881, a candidate targeting familial adenomatous polyposis, a rare inherited condition. It also reported a milestone payment from Sanofi after the partner optioned a drug candidate, and it completed a follow-on equity offering. Despite these catalysts, the stock has struggled over a longer horizon, trading near multi-year lows and well below its 2021 initial public offering price. Persistent cash burn, an unprofitable operating model, and reliance on milestone-based collaboration revenue continue to shape sentiment.
Twist Bioscience manufactures synthetic DNA on a silicon-based platform, producing genes, gene fragments, and variant libraries used in drug discovery, diagnostics, and research. Its two main segments are next-generation sequencing (NGS) tools and synthetic biology products, and it has positioned itself as a key supplier to AI-enabled drug discovery.
TWST has delivered standout relative performance over the past year, with shares rising several-fold and revenue growing steadily for fifteen consecutive quarters. In its most recent fiscal quarter, revenue climbed roughly 28% year over year and the company posted its first quarter of positive adjusted EBITDA. AI-related drug discovery sales grew sharply. However, recent weeks have introduced volatility: the company's forward guidance implied a slower growth trajectory for AI revenue than some investors anticipated, and a short-seller report questioned the depth of its AI-partnership narrative. The stock pulled back from highs even as the underlying business continued to expand gross margin and narrow losses.
The two companies serve complementary but distinct roles. RXRX is an asset-owner betting on its own AI platform to generate drug candidates and partnership value, making it highly dependent on clinical milestones and collaboration revenue. TWST is a tools-and-services provider selling "picks and shovels" to the broader discovery ecosystem, generating recurring commercial revenue today.
On momentum, TWST holds a clear advantage, with strong relative strength and a share price near the upper end of its range despite a recent pullback. RXRX has lagged, with negative year-to-date performance and a persistent downtrend punctuated by occasional catalyst rallies.
Risk profiles also differ. RXRX faces clinical and execution risk, with no approved product and ongoing dilution from capital raises. TWST faces valuation and sentiment risk, trading at a premium multiple of sales while still unprofitable on a GAAP (Generally Accepted Accounting Principles) basis and subject to short-seller scrutiny and heavy insider selling.
Based on observable factors, Tickeron's AI would currently favor TWST over RXRX. Twist Bioscience demonstrates stronger trend consistency, superior relative performance, accelerating revenue growth, and a meaningful profitability inflection with its first positive adjusted EBITDA quarter. While its premium valuation and the recent guidance-driven pullback introduce caution, these are outweighed in the current framework by its clearer momentum and improving fundamentals. Recursion offers notable catalysts but remains constrained by a longer-term downtrend and an unprofitable, milestone-dependent model. The assessment is probabilistic rather than definitive and reflects current market positioning rather than a permanent judgment.
In my own work, I often rely on Tickeron’s AI Screener to quickly filter and compare names like these across sectors. It surfaces data on momentum, fundamentals, and relative strength that complements traditional research and helps me stay objective when evaluating contrasting stories in the same space.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend. In 28 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 62 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for TWST turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TWST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 63 cases where TWST's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
Following a +10.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.596). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 43 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology